IDEAS home Printed from https://ideas.repec.org/a/abf/journl/v18y2019i1p13211-13252.html
   My bibliography  Save this article

The Importance of Biological Invariance in Drug Design

Author

Listed:
  • Oscar à lvarez
  • Fernández Martínez Juan Luis

    (Department of Mathematics, Spain)

Abstract

Drug design and discovery is one of the forefront challenges within the pharmaceutical industries...

Suggested Citation

  • Oscar à lvarez & Fernández Martínez Juan Luis, 2019. "The Importance of Biological Invariance in Drug Design," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 18(1), pages 13211-13212, May.
    • Handle: RePEc:abf:journl:v:18:y:2019:i:1:p:13211-13252
    DOI: 10.26717/BJSTR.2019.18.003086
    as

    Download full text from publisher

    File URL: https://biomedres.us/pdfs/BJSTR.MS.ID.003086.pdf
    Download Restriction: no
    File URL: https://biomedres.us/fulltexts/BJSTR.MS.ID.003086.php
    Download Restriction: no
    File URL: https://libkey.io/10.26717/BJSTR.2019.18.003086?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    2. Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
    3. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    4. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    5. Sam Peltzman, 2022. "“The theory of economic regulation” after 50 years," Public Choice, Springer, vol. 193(1), pages 7-21, October.
    6. Unsal, Omer & Houston, Reza, 2024. "R&D grants and medical innovation," Journal of Economics and Business, Elsevier, vol. 128(C).
    7. Bae, Joonhyung & Ozmel, Umit, 2024. "The interplay between product development failures and alliance portfolio properties in the formation of exploration versus exploitation alliances," Journal of Business Research, Elsevier, vol. 177(C).
    8. Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
    9. Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
    10. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    11. Thakur-Wernz, Pooja & Bruyaka, Olga & Contractor, Farok, 2020. "Antecedents and relative performance of sourcing choices for new product development projects," Technovation, Elsevier, vol. 90.
    12. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    13. Joshua Krieger & Danielle Li & Dimitris Papanikolaou, 2022. "Missing Novelty in Drug Development," The Review of Financial Studies, Society for Financial Studies, vol. 35(2), pages 636-679.
    14. Maya M. Durvasula & Sabri Eyuboglu & David M. Ritzwoller, 2024. "Distilling Data from Large Language Models: An Application to Research Productivity Measurement," Papers 2405.08030, arXiv.org, revised Dec 2024.
    15. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
    16. Vincenzo Atella & Joanna Kopinska, 2018. "New Technologies and Costs," CEIS Research Paper 442, Tor Vergata University, CEIS, revised 09 Aug 2018.
    17. Yixiang Ruan & Chenyin Lu & Ning Xu & Yuchen He & Yixin Chen & Jian Zhang & Jun Xuan & Jianzhang Pan & Qun Fang & Hanyu Gao & Xiaodong Shen & Ning Ye & Qiang Zhang & Yiming Mo, 2024. "An automatic end-to-end chemical synthesis development platform powered by large language models," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    18. Hassan Heidari & Arash Refah Kahriz & Yousef Mohammadzadeh, 2019. "Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors," Economic Change and Restructuring, Springer, vol. 52(3), pages 255-277, August.
    19. Oliver, Edward & Kourouklis, Dimitrios & Jofre-Bonet, Mireia, 2024. "Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach," Research Policy, Elsevier, vol. 53(8).
    20. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.

    More about this item

    Keywords

    Biomedical Sciences; Biomedical Research; Technical Research; Genomics; Drug Design; Drug Repositioning; Biological Invariance;
    All these keywords.

    JEL classification:

    • R00 - Urban, Rural, Regional, Real Estate, and Transportation Economics - - General - - - General
    • Z0 - Other Special Topics - - General

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:abf:journl:v:18:y:2019:i:1:p:13211-13252. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Angela Roy (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.